Publication: Comparison of direct oral anticoagulants and low-molecular-weight heparins in cancer patients with nonvalvular atrial fibrillation: insights from a single-center experience
Program
KU-Authors
KU Authors
Co-Authors
Ceren, İ.
Şener, Y. Z.
Göçer, K.
Gülgün Fırat, H.
Yıldız, F.
Bozduman Habip, F.
Açıkgöz, E.
Ateş, Ö.
Gerede Uludağ, D. M.
Eroğlu Büyüköner, E.
Editor & Affiliation
Compiler & Affiliation
Translator
Other Contributor
Date
Language
eng
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Atrial fibrillation (AF) is frequently encountered in patients with cancer and poses challenges for anticoagulant management. The present study was conducted to compare clinical outcomes associated with direct oral anticoagulants (DOACs) and low-molecular-weight heparin (LMWH) in individuals with active malignancy and nonvalvular AF (NVAF). METHODS: Data from patients with active cancer who received LMWH or DOACs for NVAF were retrospectively screened. Efficacy, safety, and survival outcomes were analyzed. RESULTS: The study enrolled 222 patients, of whom 25.7% received LMWH and 74.3% received DOACs. Cancer stage, type, and treatment were comparable between groups. The DOAC group had higher CHA2DS2-VA (3.13 ± 1.21 vs. 2.42 ± 1.33; P
Source
Publisher
Kare
Subject
Health sciences, Medicine, Cardiology and cardiovascular medicine
Citation
Has Part
Source
Anatolian Journal of Cardiology
Book Series Title
Edition
DOI
10.14744/anatoljcardiol.2026.5923
item.page.datauri
Link
Rights
N/A
Copyrights Note
Creative Commons license
Except where otherwised noted, this item's license is described as N/A